

# MosaiQ AiPlex<sup>®</sup> APS

Antiphospholipid Syndrome Microarray Solution

Coming soon



Provides comprehensive Antiphospholipid Syndrome diagnostic and workflow efficiency



A classification of APS patients was described in 1999 and revised in 2006. It was updated in August 2023 and supported by the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR).<sup>1</sup>

**aCL**  
IgG/IgM

**Anti-Cardiolipin (aCL)**

– recognized for its good sensitivity<sup>3</sup>

**aβ2GPI**  
IgG/IgM

**Anti-β2 Glycoprotein I (aβ2GPI)**

– recognized for its good specificity<sup>3</sup>

**Antiphospholipid syndrome (APS)** is a chronic, **systemic autoimmune disease** characterized by vascular thrombosis (blood clots), pregnancy complications (such as recurrent early miscarriages and late pregnancy losses), and other organ-related symptoms. These events occur in individuals who test persistently positive for **antiphospholipid antibodies (aPL)**.<sup>1,3</sup>

While there is no known cure, early identification and appropriate treatment are key to reducing the risk of complications and improving outcomes.<sup>1,2</sup>

AliveDx **planar microarray supporting diagnosis, AiPlex APS**, is designed to deliver rapid in-vitro test results, **helping to reduce the time to results for patients**. The MosaiQ solution supports the potential urgency of these tests, combining multiple results in one single test with no calibration required.

**AliveDx**

# Fast, Easy, Comprehensive MosaiQ AiPlex APS



**Contains key markers recommended by the 2023 ACR/EULAR Antiphospholipid Syndrome classification criteria.<sup>3</sup>**

It considers both clinical and laboratory features.

Apart from an aPL test by coagulation-based functional assay, the laboratory criteria include the detection of both isotypes IgG and IgM for a $\beta$ 2GPI and aCL.<sup>3</sup>



**Generates multiple insights in one report with only 20  $\mu$ l patient sample.** One microarray provides up to 4 individual results.



**Reduces hands-on time and storage space** with ready to use, concentrated onboard reagents and buffers.



**Saves time while avoiding human errors** with a standardized master curve embedded into RFID\* tags, included with all reagents and microarrays.<sup>4</sup>



**Provides important insights** as it contains the main classification markers and isotypes.

\* RFID: Radio Frequency Identification

**The MosaiQ AiPlex APS panel, run on the MosaiQ platform, is designed to help reduce time to results for patients with Antiphospholipid Syndrome.**



## Simple Workflow

- Patients sample in, result out in one single step
- QC and calibration embedded



## Fast Results

- Results within one day
- One sample tube (low volume) for multiple tests



## Actionable Insights

- Panels help streamline clinical decision-making for physicians
- Comprehensive panels simplify complex testing pathways

1 Arachchilage DJ et al. BSH Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2024;205(3):855-880.

2 Tektonidou MG et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304.

3 Barbhaiya M et al. The 2023 ACR/EULAR APS Classification Criteria. Arthritis Rheumatol. 2023;75(10):1687-1702.

4 Sénant M et al. Increased Performances of the Biological Diagnosis of the Antiphospholipid Syndrome by the Use of a Multiplex Assay. J Immunol Res. 2015;2015:983094.



Find out more!

© AliveDx Suisse SA, 2025. The AliveDx logo, AliveDx, MosaiQ AiPlex, AiPlex and MosaiQ are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories subject to clearance in other territories.  
xxxxxxxxxxx

# AliveDx